The Spanish start-up Minoryx Therapeutics recently opened a subsidiary in Belgium to further their research on treatments for rare and orphan diseases. Co-founder and CEO Marc Martinell spoke to BioVox about his personal reasons for founding the company and why Belgium is such an attractive location to start-ups in the medical sector.
The microbiome had been at the forefront of a lot of research and news in the past few years. Now, a new study published in Nature Microbiology has linked specific microbiome changes with depression and quality of life. The largest of its kind to-date, the research was made possible by over 2000 participants from the Flemish Gut Flora Project and the Dutch LifeLines DEEP project. The results may lead to novel therapies for people suffering from this debilitating mental illness.
The Spanish start-up Minoryx Therapeutics recently opened a subsidiary in Belgium to further their research on treatments for rare and orphan diseases. Co-founder and CEO Marc Martinell spoke to BioVox about his personal reasons for founding the company and why Belgium is such an attractive location to start-ups in the medical sector.
The microbiome had been at the forefront of a lot of research and news in the past few years. Now, a new study published in Nature Microbiology has linked specific microbiome changes with depression and quality of life. The largest of its kind to-date, the research was made possible by over 2000 participants from the Flemish Gut Flora Project and the Dutch LifeLines DEEP project. The results may lead to novel therapies for people suffering from this debilitating mental illness.